Skip to main content
. 2018 Jan 22;2018:6026315. doi: 10.1155/2018/6026315

Table 3.

Relationship between MD and tumor subtype (overall and stratified by menopausal status) among women included in this study.

Clinical characteristic n (%) Percent density (%) Absolute dense area Nondense area
Unadjusted Adjusted∗∗ Unadjusted Adjusted∗∗ Unadjusted Adjusted∗∗
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
All women
ER status
 Negative 33 27 20.0 16.7 23.3 19.3 16.2 22.4 61.2 47.7 74.7 63.2 49.9 76.6 280.3 232.7 327.8 286.0 242.7 329.3
 Positive 90 73 25.9 23.7 28.2 25.8 23.7 28.0 92.8 82.7 102.9 94.4 84.8 104.1 266.1 238.0 294.2 274.1 249.0 299.2
P value 0.04 0.02 0.01 0.01 0.73 0.76
Premenopausal women
ER status
 Negative 9 21 24.5 17.5 31.6 25.0 16.7 33.4 73.6 44.1 103.1 63.3 31.0 95.6 249.2 178.4 320.0 216.4 140.7 292.1
 Positive 33 79 32.5 28.3 36.8 32.2 27.7 36.7 103.4 85.0 121.8 104.8 85.0 124.6 205.4 171.7 239.1 209.7 174.5 244.8
P value 0.19 0.31 0.25 0.16 0.45 0.95
Postmenopausal women
ER status
 Negative 24 30 18.4 14.9 22.0 17.0 13.8 20.1 57.3 42.4 72.3 64.4 50.5 78.4 293.6 233.6 353.5 336.8 283.5 390.2
 Positive 57 70 22.5 20.0 25.0 22.9 20.6 25.3 87.2 75.1 99.2 88.6 78.0 99.3 305.4 265.7 345.2 304.5 271.5 337.5
P value 0.20 0.05 0.04 0.07 0.81 0.48
All women
PR status
 Negative 40 33 22.0 18.9 25.2 22.4 19.2 25.5 65.0 52.3 77.7 71.4 58.2 84.5 250.9 210.1 291.7 259.2 221.6 296.9
 Positive 83 67 25.4 23.0 27.7 24.8 22.6 27.1 93.5 82.9 104.1 92.7 82.6 102.7 279.3 249.4 309.2 285.6 259.0 312.2
P value 0.25 0.38 0.02 0.08 0.43 0.43
Premenopausal women
PR status
 Negative 11 26 26.0 19.4 32.6 28.1 19.9 36.3 78.4 50.7 106.1 78.1 44.7 111.5 241.4 178.2 304.6 217.0 148.1 285.9
 Positive 31 74 32.5 28.1 36.9 31.7 27.0 36.4 103.5 84.4 122.5 102.5 81.6 123.4 205.3 170.5 240.1 209.1 172.4 245.8
P value 0.27 0.59 0.31 0.40 0.50 0.92
Postmenopausal women
PR status
 Negative 29 36 20.7 17.3 24.1 19.5 16.3 22.7 60.6 46.6 74.7 68.5 55.2 81.9 255.4 205.3 305.6 296.9 250.8 343.0
 Positive 52 64 21.6 18.9 24.2 21.9 19.5 24.4 88.1 75.4 100.8 88.2 77.1 99.3 329.5 286.9 372.1 323.4 288.1 358.7
P value 0.77 0.41 0.05 0.12 0.13 0.53
All women
TNBC status
 No 95 77 25.8 23.5 28.0 26.1 23.9 28.2 92.9 83.1 102.7 96.6 87.4 105.7 271.3 244.6 298.1 279.2 255.5 302.8
 Yes 21 17 20.1 15.9 24.3 17.4 13.6 21.1 58.7 42.2 75.2 56.3 41.1 71.4 266.5 210.2 322.8 287.2 234.9 339.4
P value 0.11 0.01 0.02 <0.01 0.89 0.87
Premenopausal women
TNBC status
 No 33 85 33.1 28.7 37.4 33.1 28.6 37.6 111.6 93.9 129.3 115.7 97.9 133.5 218.9 187.8 250.0 225.0 193.6 256.4
 Yes 6 15 22.0 13.7 30.2 19.0 10.4 27.5 54.1 25.7 82.5 37.3 12.5 62.1 222.9 149.7 296.1 216.7 139.3 294.1
P value 0.12 0.07 0.04 0.01 0.98 0.85
Postmenopausal women
TNBC status
 No 62 81 22.3 19.8 24.7 22.9 20.6 25.2 83.8 72.2 95.4 87.6 77.2 98.0 301.9 264.2 339.7 306.7 274.4 339.1
 Yes 15 19 19.5 14.9 24.1 16.4 12.4 20.4 61.4 41.4 81.4 64.0 45.8 82.2 286.7 212.1 361.3 331.9 262.9 400.9
P value 0.46 0.07 0.19 0.13 0.78 0.66
All women
HER2 status
 Negative 94 76 24.2 22.0 26.4 23.8 21.7 25.8 83.1 73.6 92.6 86.4 77.4 95.5 270.2 243.3 297.1 284.8 260.8 308.8
 Positive 22 18 26.9 22.1 31.7 27.4 22.8 32.1 99.5 78.1 121.0 99.3 78.9 119.7 271.4 215.9 327.0 262.0 213.6 310.5
P value 0.49 0.32 0.33 0.43 0.99 0.55

∗∗Adjusted for age and BMI and additionally adjusted for menopausal status in analyses that included all women. BMI: body mass index; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor; TNBC: triple negative breast cancer; CI: confidence intervals.